Ivo W. Tremont-Lukats
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ivo W. Tremont-Lukats has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Prashant Rai
Neurology, University of Texas Medical Branch, Galveston, USA
4 shared publications Akhil Shivaprasad
Department of Neurology, Southern Illinois University, Springfield, Illinois
3 shared publications- Bhanu Gogia
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (S.M., S.P.C., B.G., J.-Y.W., A.S., S.K.).
3 shared publications - Bin S. Teh
Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX 77030, USA
2 shared publications Sudhakar Tummala
MD Anderson Cancer Center
2 shared publications- Sudhakar Tummala
The University of Texas MD Anderson Cancer Center
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Radiology
- Vol. 2026 (1)
A Case of Physiologic Enhancement of Scarpa′s Ganglia Mimicking Bilateral Vestibular Schwannomas in a Patient With Atypical Meningioma With NF2 Mutation
We followed a 36‐year‐old man with an atypical meningioma with somatic NF2 mutation and invasion into the bone, temporalis muscle, and pterygopalatine fossa, treated with surgical resection and adjuvant radiation therapy. His medical history included medulloblastoma treated with resection and adjuvant radiation therapy and a WHO Grade 1 meningioma treated with gross total resection. A brain MRI during routine follow‐up revealed small enhancing foci in both internal auditory canals (IACs), which prompted concern for bilateral vestibular schwannomas and suspect NF2‐related schwannomatosis (NF2‐SWN). However, the lesions were symmetric, fundal, and nonnodular on high‐resolution constructive interference in steady‐state (CISS) imaging, with smooth vestibular nerve contours, long‐term interval stability, and a lack of clinical symptoms, favoring physiologic enhancement of the vestibular ganglia (Scarpa′s ganglia) rather than vestibular schwannomas. Recognition of these distinguishing features also helped avoid associating the IAC findings with the known NF2 mutation, which was determined to be somatic. While germline NF2 mutations (NF2‐SWN) often lead to meningiomas and vestibular schwannomas, somatic NF2 mutations are common in sporadic meningiomas and should not suggest NF2‐SWN. This case highlights the need to correlate small enhancing IAC foci with morphology on CISS MRI, symmetry, longitudinal stability, and NF2 pathology to avoid misdiagnosis of enhancing Scarpa′s ganglia as vestibular schwannomas, as misdiagnosis can lead to increased patient anxiety and unnecessary follow‐ups.
- 1 January 2026
- Published by Wiley in Case Reports in Radiology
- Vol. 2026 (1)
Open AccessA Case of Physiologic Enhancement of Scarpa′s Ganglia Mimicking Bilateral Vestibular Schwannomas in a Patient With Atypical Meningioma With NF2 Mutation
We followed a 36‐year‐old man with an atypical meningioma with somatic NF2 mutation and invasion into the bone, temporalis muscle, and pterygopalatine fossa, treated with surgical resection and adjuvant radiation therapy. His medical history included medulloblastoma treated with resection and adjuvant radiation therapy and a WHO Grade 1 meningioma treated with gross total resection. A brain MRI during routine follow‐up revealed small enhancing foci in both internal auditory canals (IACs), which prompted concern for bilateral vestibular schwannomas and suspect NF2‐related schwannomatosis (NF2‐SWN). However, the lesions were symmetric, fundal, and nonnodular on high‐resolution constructive interference in steady‐state (CISS) imaging, with smooth vestibular nerve contours, long‐term interval stability, and a lack of clinical symptoms, favoring physiologic enhancement of the vestibular ganglia (Scarpa′s ganglia) rather than vestibular schwannomas. Recognition of these distinguishing features also helped avoid associating the IAC findings with the known NF2 mutation, which was determined to be somatic. While germline NF2 mutations (NF2‐SWN) often lead to meningiomas and vestibular schwannomas, somatic NF2 mutations are common in sporadic meningiomas and should not suggest NF2‐SWN. This case highlights the need to correlate small enhancing IAC foci with morphology on CISS MRI, symmetry, longitudinal stability, and NF2 pathology to avoid misdiagnosis of enhancing Scarpa′s ganglia as vestibular schwannomas, as misdiagnosis can lead to increased patient anxiety and unnecessary follow‐ups.
- 23 April 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (3) , 613-623
Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases
Purpose Leptomeningeal metastases (LM) are an aggressive complication of metastatic breast cancer (MBC) with brain metastases (BM), with a short survival of weeks to months. Studies suggest that surgical resection of BM may increase the risk of LM, especially in infratentorial metastases. In this retrospective study, we examine this and other factors which may be associated with increased risk of LM. Methods A database search at a single institution identified 178 patients with MBC and treated BM between 2007 and 2020. We collected demographic, clinical, radiographic, and other treatment data. LM was diagnosed by cerebrospinal fluid (CSF) cytology, neuroimaging, or both. Cox proportional hazards model was used. Results After a median follow-up of 8.5 months, 41 out of 178 patients (23%) with BM developed LM. Median time to develop LM was 130 days. Mean age was 51.3 years. The number and size of the BM, hemorrhagic/cystic lesions, progressive/stable systemic disease, and extracranial metastases sites other than liver did not pose a higher risk of LM. Infratentorial lesions (HR = 5.41) and liver metastases (HR = 2.28) had a higher risk of LM. Patients who had any surgery did not have a higher risk for LM (HR 1.13). The LM group had a worse overall survival as compared to the non-LM group. Conclusion Among MBC patients with BM, infratentorial BM and visceral liver lesions increase the risk of LM, whereas local treatment modalities such as surgery and radiation do not. These data imply that local treatment strategy should not differ based on potential risk for LM.
- 23 April 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (3) , 613-623
Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases
Purpose Leptomeningeal metastases (LM) are an aggressive complication of metastatic breast cancer (MBC) with brain metastases (BM), with a short survival of weeks to months. Studies suggest that surgical resection of BM may increase the risk of LM, especially in infratentorial metastases. In this retrospective study, we examine this and other factors which may be associated with increased risk of LM. Methods A database search at a single institution identified 178 patients with MBC and treated BM between 2007 and 2020. We collected demographic, clinical, radiographic, and other treatment data. LM was diagnosed by cerebrospinal fluid (CSF) cytology, neuroimaging, or both. Cox proportional hazards model was used. Results After a median follow-up of 8.5 months, 41 out of 178 patients (23%) with BM developed LM. Median time to develop LM was 130 days. Mean age was 51.3 years. The number and size of the BM, hemorrhagic/cystic lesions, progressive/stable systemic disease, and extracranial metastases sites other than liver did not pose a higher risk of LM. Infratentorial lesions (HR = 5.41) and liver metastases (HR = 2.28) had a higher risk of LM. Patients who had any surgery did not have a higher risk for LM (HR 1.13). The LM group had a worse overall survival as compared to the non-LM group. Conclusion Among MBC patients with BM, infratentorial BM and visceral liver lesions increase the risk of LM, whereas local treatment modalities such as surgery and radiation do not. These data imply that local treatment strategy should not differ based on potential risk for LM.
- Open Access
- 29 January 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (3) , 723-725
COVID‐19 encephalopathy, Bayes rule, and a plea for case–control studies
- 29 January 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (3) , 723-725
Open AccessCOVID‐19 encephalopathy, Bayes rule, and a plea for case–control studies
- Open Access
- 14 October 2020
- Published by Wiley in Epilepsia Open
- Vol. 5 (4) , 616-617
Epileptic discharges in acutely ill patients investigated for SARS‐CoV‐2/COVID‐19 and the absence of evidence
- 14 October 2020
- Published by Wiley in Epilepsia Open
- Vol. 5 (4) , 616-617
Open AccessEpileptic discharges in acutely ill patients investigated for SARS‐CoV‐2/COVID‐19 and the absence of evidence
- 28 July 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 22 (11) , 1708-1709
DEPOSEIN: Take with a grain of salt
- 28 July 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 22 (11) , 1708-1709
DEPOSEIN: Take with a grain of salt
- Open Access
- 20 May 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 7 (6) , 583-588
Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma
Patients with primary brain tumors often experience seizures, which can be the presenting symptom or occur for the first time at any point along the illness trajectory. In addition to causing morbidity, seizures negatively affect independence and quality of life in other ways, for example, by leading to loss of driving privileges. Long-term therapy with antiepileptic drugs (AEDs) is the standard of care in brain tumor patients with seizures, but the role of prophylactic AEDs in seizure-naive patients remains controversial. In this article, experts in the field discuss the issues of AED efficacy and toxicity, and explain their differing recommendations for routine use of prophylactic AEDs.
- 20 May 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 7 (6) , 583-588
Open AccessNeuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma
Patients with primary brain tumors often experience seizures, which can be the presenting symptom or occur for the first time at any point along the illness trajectory. In addition to causing morbidity, seizures negatively affect independence and quality of life in other ways, for example, by leading to loss of driving privileges. Long-term therapy with antiepileptic drugs (AEDs) is the standard of care in brain tumor patients with seizures, but the role of prophylactic AEDs in seizure-naive patients remains controversial. In this article, experts in the field discuss the issues of AED efficacy and toxicity, and explain their differing recommendations for routine use of prophylactic AEDs.
- Open Access
- 1 December 2019
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 8 (Suppl 6) , S589-S591
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
- 1 December 2019
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 8 (Suppl 6) , S589-S591
Open AccessLomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
- 14 May 2016
- Published by Springer Nature
- p. 149-159
Oncologic Emergencies of the Central Nervous System (CNS)
- 14 May 2016
- Published by Springer Nature
- p. 149-159
Oncologic Emergencies of the Central Nervous System (CNS)